Latest Breaking News On - Platinum resistant ovarian - Page 1 : comparemela.com

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.

Cambridge
Cambridgeshire
United-kingdom
New-york
United-states
Vancouver
British-columbia
Canada
Toronto
Ontario
Tsawwassen
Ottawa

Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call Transcript

Operator: Greetings. Welcome to Panbela Therapeutics Fourth Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

China
Texas
United-states
Australia
American
Jennifer-simpson
Josh-korsen
Jonathan-aschoff
Joe-pantginis
Eflornithine-pediatric-neuroblastoma-program
American-society-of-hematology
Stock-market-exchange

Global Ovarian Cancer Drug Trial Led by Stephenson Researcher

Global Ovarian Cancer Drug Trial Led by Stephenson Researcher
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Oklahoma
United-states
Kathleen-moore
Mirvetuximab-soravtansine
European-network-of-gynaecological-oncological-trial-groups
Drug-administration
Ou-health-sciences
Ou-health-stephenson-cancer-center
Stephenson-cancer-center
Ou-college-of-medicine
Gynecologic-oncology-group-partners
New-england-journal

FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

FDA Grants Priority Review of ImmunoGen's Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United-states
China
American
Michael-vasconcelles
Immunogen-inc
Exchange-commission-on
National-medical-products-administration-of-china
American-society-of-clinical-oncology
Drug-administration
Nasdaq
Company-annual-report-on-form
Company-quarterly-reports-on-form

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Boston
Massachusetts
United-states
Markus-renschler
International-conference-on-molecular
Exchange-commission
Cyteir-therapeutics-inc
Cyteir-therapeutics
Expansion-results
Monocarboxylate-transporter
Platinum-resistant-ovarian
Molecular-targets